Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:IRTCNASDAQ:NARINASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.56-1.6%$7.37$5.28▼$14.38$539.69M0.95362,317 shs36,901 shsIRTCiRhythm Technologies$144.80-0.1%$119.99$55.92▼$146.90$4.62B1.34481,665 shs30,590 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.34 million shsN/ATMDXTransMedics Group$129.69+0.7%$97.54$55.00▼$177.37$4.38B2.11.35 million shs139,826 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+3.42%+1.99%-9.26%-34.64%-0.60%IRTCiRhythm Technologies+3.08%-0.95%+10.57%+34.64%+72.45%NARIInari Medical0.00%0.00%0.00%0.00%+59.02%TMDXTransMedics Group+3.87%+0.16%+43.08%+90.90%-3.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.4657 of 5 stars3.30.00.00.03.24.21.3IRTCiRhythm Technologies1.3178 of 5 stars2.53.00.00.02.30.00.6NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ATMDXTransMedics Group1.8362 of 5 stars1.43.00.00.02.72.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$14.33118.66% UpsideIRTCiRhythm Technologies 2.91Moderate Buy$133.73-7.65% DownsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideTMDXTransMedics Group 2.82Moderate Buy$126.70-2.30% DownsideCurrent Analyst Ratings BreakdownLatest BVS, NARI, IRTC, and TMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.005/2/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $151.004/29/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.004/23/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.95$0.52 per share12.58$2.80 per share2.34IRTCiRhythm Technologies$618.59M7.47N/AN/A$6.85 per share21.14NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91TMDXTransMedics Group$488.23M8.98$0.24 per share530.08$4.20 per share30.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.25N/A-7.11%15.61%4.01%N/AIRTCiRhythm Technologies-$123.41M-$3.14N/AN/AN/A-19.14%-118.83%-11.34%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ATMDXTransMedics Group-$25.03M$1.36137.7990.69N/A8.14%18.74%4.39%7/30/2025 (Estimated)Latest BVS, NARI, IRTC, and TMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99IRTCiRhythm Technologies9.006.276.12NARIInari MedicalN/A1.771.40TMDXTransMedics Group2.428.207.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%IRTCiRhythm TechnologiesN/ANARIInari Medical90.98%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipBVSBioventus32.90%IRTCiRhythm Technologies1.10%NARIInari Medical10.60%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableIRTCiRhythm Technologies1,79031.93 million31.09 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableTMDXTransMedics Group21033.82 million31.21 millionOptionableBVS, NARI, IRTC, and TMDX HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities InvestigationJune 3 at 10:00 AM | accessnewswire.comTransMedics Group's (TMDX) "Hold" Rating Reaffirmed at Needham & Company LLCJune 3 at 8:11 AM | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX) and Merck & Company (MRK)June 3 at 6:36 AM | theglobeandmail.comWellington Management Group LLP Cuts Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 3 at 4:27 AM | marketbeat.comTransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?June 2 at 10:55 AM | zacks.comUniversal Beteiligungs und Servicegesellschaft mbH Buys New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)June 2 at 4:34 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities InvestigationJune 1 at 10:00 AM | accessnewswire.comNuveen Asset Management LLC Reduces Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 1 at 3:45 AM | marketbeat.comEdward M. Basile Sells 5,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 31, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $632,250.00 in StockMay 30, 2025 | insidertrades.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach OutMay 29, 2025 | accessnewswire.comSpotlight on TransMedics Group Inc Top Companies in the NasdaqMay 29, 2025 | kalkinemedia.comKuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law FirmMay 27, 2025 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 27, 2025 | prnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach OutMay 27, 2025 | accessnewswire.comGF Fund Management CO. LTD. Purchases Shares of 23,035 TransMedics Group, Inc. (NASDAQ:TMDX)May 27, 2025 | marketbeat.comMackenzie Financial Corp Buys 349,403 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)May 27, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 27, 2025 | marketbeat.comProShare Advisors LLC Has $627,000 Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 27, 2025 | marketbeat.comAmeriprise Financial Inc. Has $6.10 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 26, 2025 | marketbeat.comAnalysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $126.70May 26, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketThese 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesSurvey: America’s Most Inspirational Women Business Leaders [2025]By MarketBeat Staff | May 7, 2025View Survey: America’s Most Inspirational Women Business Leaders [2025]BVS, NARI, IRTC, and TMDX Company DescriptionsBioventus NYSE:BVS$6.56 -0.11 (-1.58%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.iRhythm Technologies NASDAQ:IRTC$144.80 -0.18 (-0.12%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.TransMedics Group NASDAQ:TMDX$129.69 +0.95 (+0.73%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
